Skip to content
Gold Mining News – Lifestyle
Home
Sample Page
Author:
Egetis Therapeutics
Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026
May 19, 2026
Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026
May 7, 2026
Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S.
May 5, 2026
Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026
April 30, 2026
Egetis Appoints Tiago Nunes as Chief Medical Officer
April 9, 2026
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency
March 27, 2026